Dual HER2 inhibition and paclitaxel in metastatic breast cancer

被引：0
作者：
Brower, Vicki
机构：
来源：
LANCET ONCOLOGY | 2015年 / 16卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(14)71201-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E57 / E57
页数：1
相关论文
共 50 条
  • [31] Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
    Emde, Anna
    Mahlknecht, Georg
    Maslak, Kerstin
    Ribba, Benjamin
    Sela, Michael
    Possinger, Kurt
    Yarden, Yosef
    TRANSLATIONAL ONCOLOGY, 2011, 4 (05): : 293 - 300
  • [32] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [33] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [34] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
    Kong, Sun-Young
    Nam, Byung-Ho
    Lee, Keun Seok
    Kwon, Youngmee
    Lee, Eun Sook
    Seong, Moon-Woo
    Lee, Do Hoon
    Ro, Jungsil
    CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515
  • [36] Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer
    Astvatsaturyan, K.
    Bose, S.
    MODERN PATHOLOGY, 2013, 26 : 28A - 28A
  • [37] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2013, 93 : 28A - 28A
  • [39] HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Chafika Mazouni
    Cornelia Liedtke
    Shu-Wan Kau
    Debby Frye
    Marjorie Green
    Ana M. Gonzalez-Angulo
    W. Fraser Symmans
    Gabriel N. Hortobagyi
    Lajos Pusztai
    Breast Cancer Research and Treatment, 2008, 108 : 183 - 190
  • [40] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
12345